Compare BLBD & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | ENOV |
|---|---|---|
| Founded | 1927 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Fluid Controls |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2008 |
| Metric | BLBD | ENOV |
|---|---|---|
| Price | $50.43 | $27.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $64.60 | $51.17 |
| AVG Volume (30 Days) | 422.6K | ★ 815.6K |
| Earning Date | 11-24-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.79 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | $1,480,099,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $4.86 | $9.27 |
| Revenue Next Year | $3.41 | $4.56 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | 9.87 | ★ 11.57 |
| 52 Week Low | $30.04 | $25.47 |
| 52 Week High | $61.95 | $49.38 |
| Indicator | BLBD | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 36.08 |
| Support Level | $50.48 | $26.69 |
| Resistance Level | $51.65 | $30.93 |
| Average True Range (ATR) | 2.01 | 1.33 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 20.23 | 7.31 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.